Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440637 | 0.89 | DGAT1 (0.53) | DGAT1HPGDMAPT | |
| SCHEMBL441311 | 0.87 | HPGD (0.55) | DGAT1HPGDMAPT | |
| SCHEMBL441095 | 0.86 | DGAT1 (0.54) | DGAT1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL10279768 | 0.86 | DGAT1 (0.55) | DGAT1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL463426 | 0.83 | DGAT1 (0.51) | DGAT1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL439190 | 0.83 | DGAT1 (0.51) | DGAT1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL437430 | 0.82 | DGAT1 (0.50) | DGAT1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL440361 | 0.82 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL438032 | 0.81 | DGAT1 (0.51) | DGAT1HPGDUSP5 | |
| SCHEMBL437986 | 0.81 | DGAT1 (0.55) | DGAT1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885HPGD 1034/4885CHRM2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.